The study is the longest observation to date of patients with advanced Merkel cell carcinoma receiving first-line pembrolizumab.
A recent model by Massachusetts General Hospital projects that without proper policy, public health and health care delivery efforts, the opioid overdose epidemic will increase.
Top news of the day across the health care landscape.
Top news of the week from Specialty Pharmacy Times.
The findings are further evidence of the impact of an active lifestyle on physical health.
Ado-trastuzumab emtansine (Kadcyla) is currently approved for the treatment of patients with HER-2 positive metastatic breast cancer who previously received trastuzumab and a taxane.
The proposed rule aims to encourage drug manufacturers to pass discounts directly to patients and improve transparency in the market.

Most Popular

Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.